Home/Vandria/Leila Mirmohamadsadeghi, PhD

LM

Leila Mirmohamadsadeghi, PhD

Director Preclinical Operations

Therapeutic Areas

CNS Musculoskeletal Pulmonary Hepatic

Vandria Pipeline

Drug	Indication	Phase
VNA-318	Cognitive Impairment (Alzheimer's Disease, Major Depressive Disorder)	Phase 1

Leadership Team at Vandria

Chief Executive Officer

Pénélope Andreux, PharmD, PhD

Chief Scientific Officer

Peter Harboe-Schmidt, MSc, MBA

Head BD & Finance

Chief Medical Officer

View full Vandria profile